- Researchers in a clinical trial looked at 562 COVID-19 patients who are at high risk of developing serious illness with half given remdesivir.
- Currently, remdesivir is the only drug approved by the FDA to treat critically ill coronavirus patients
- After four weeks, 5.3% of the drug group were hospitalized compared to 0.7% of the placebo group, reducing the risk of hospitalization by 87%.
- Additionally, 8.3% of the placebo group had sought medical care compared to 1.6% of the treatment group, leading to an 81% reduction in the risk of medical visit.
Remdesivir reduces the risk of hospitalization and medical visits due to COVID-19 in high-risk patients, new data suggests.
California-based Gilead Sciences Inc., maker of antiviral drug, published Result Its Phase III clinical trial on Wednesday.
The researchers found that patients treated with remdesivir were 87 percent less likely to be hospitalized and required 81 fewer medical visits than those who were given a placebo.
The team says the findings suggest that remdesivir, the only drug fully approved to treat critically ill coronavirus patients, could also be used for people who are at high risk of becoming critically ill. – but are still early in their transition.
Researchers in a clinical trial looked at 562 COVID-19 patients who were at high risk of developing serious illness and half were given remdesivir, the only drug approved by the FDA to treat critically ill coronavirus patients. Was. Image: a vial of remdesivir, April 2021
Patients treated with remdesivir were 87 percent less likely to be hospitalized and 81 percent less likely to need medical attention compared to those taking a placebo. (up)
Remdesivir was developed by Gilead to treat Ebola, a deadly fever that emerged in West Africa in 2014.
While it was unsuccessful in treating Ebola, the drug appears to interfere with the ability of the coronavirus to copy its genetic material.
In April 2020, the National Institutes of Health (NIH) released the results of a study that found remdesivir helped patients recover 31 percent faster.
This led to the US Food and Drug Administration (FDA) issuing an emergency use authorization for the drug the following month.
A few months later, in October 2020, the FDA fully approved the drug for use in adults and pediatric patients aged 12 to 17 years who require hospitalization.
However, the new trial suggests that the treatment may be effective even in treating patients before they are admitted to the hospital.
Researchers looked at 562 participants at high risk of developing severe COVID-19, half of whom were given remdesivir and the other half a placebo.
After four weeks, 5.3 percent of the placebo group were hospitalized, compared to 0.7 percent of the placebo group.
The team said this shows the drug reduces the risk of hospitalization by up to 87 percent.
Additionally, the trial looked at patients who required medical visits due to COVID-19.
By day 28, 8.3 percent of the placebo group had sought medical care, compared to 1.6 percent of the treatment group.
Researchers say this means the drug reduces the risk of medical travel by up to 81 percent.
“Antiviral drugs provide maximum benefit when used early in the course of the disease,” said principal investigator Dr Robert Gottlieb, from Baylor University Medical Center and Baylor Scott & White Research Institute. Statement.
‘We are seeing a much higher number of hospitalized patients with new COVID-19 infections placing increased demands on already overburdened health systems.
‘Remdesivir, also known as Vaxlary, is an effective antiviral for the treatment of hospitalized patients with COVID-19 and is an essential tool to help reduce disease progression. ‘